Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial

التفاصيل البيبلوغرافية
العنوان: Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial
المؤلفون: Burns, Jane C, Roberts, Samantha C, Tremoulet, Adriana H, He, Feng, Printz, Beth F, Ashouri, Negar, Jain, Supriya S, Michalik, David E, Sharma, Kavita, Truong, Dongngan T, Wood, James B, Kim, Katherine K, Jain, Sonia, Anand, Vikram, Anderson, Marsha, Ang, Jocelyn, Ansusinha, Emily, Arditi, Moshe, Bartlett, Allison, Baker, Annette, Chatterjee, Archana, DeBiasi, Roberta, De Ferranti, Sarah, Dekker, Cornelia, DeZure, Chandani, Dominguez, Samuel, Erdem, Guliz, Halasa, Natasha, Harahsheh, Ashraf S., Hite, Michelle, Jaggi, Preeti, Jone, Pei-Ni, Jones, Jessica, Kaushik, Neeru, Kumar, Madan, Kurio, Gregory, Lloyd, David, Manaloor, John, McNelis, Amy, Nadipuram, Santhosh, Newburger, Jane, Newcomer, Charles, Perkins, Tiffany, Portman, Michael, Romero, José R, Rometo, Allison, Ronis, Tova, Rosenkranz, Margalit, Rowley, Anne, Samuy, Nichole, Scalici, Paul, Schuster, Jennifer, Sexson Tejtel, S. Kristen, Simonsen, Kari, Szmuszkovicz, Jacqueline, Yeh, Sylvia
المصدر: The Lancet Child & Adolescent Health; December 2021, Vol. 5 Issue: 12 p852-861, 10p
مستخلص: Although intravenous immunoglobulin (IVIG) is effective therapy for Kawasaki disease, 10–20% of patients have recrudescent fever as a sign of persistent inflammation and require additional treatment. We aimed to compare infliximab with a second infusion of IVIG for treatment of resistant Kawasaki disease.
قاعدة البيانات: Supplemental Index
الوصف
تدمد:23524642
23524650
DOI:10.1016/S2352-4642(21)00270-4